An international team of clinical collaborators, led by physician scientists from Dana-Farber Cancer Institute, performed a first-ever clinical test of the targeted therapy avapritinib in pediatric and young patients with a form of high-grade glioma. They found that the drug, already FDA-approved for certain adult cancers, was generally safe and resulted in tumor reduction visible on brain scans, as well as clinical improvement, in 3 out of 7 patients.

People diagnosed with colorectal cancer are significantly more likely to die of cardiovascular causes than the general population, especially in the first two years after their cancer diagnosis and in people younger than 50, according to a study being presented at the American College of Cardiology’s Annual Scientific Session (ACC.25).

Mammograms, with the help of artificial intelligence (AI) models, may reveal much more than cancer, according to a study being presented at the American College of Cardiology’s Annual Scientific Session (ACC.25). The findings highlight how these important cancer screening tools can also be used to assess the amount of calcium buildup in the arteries within breast tissue—an indicator of cardiovascular health.  

New Haven, Conn. — Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this technology — which allows scientists to use a “guide” RNA to modify DNA sequences and evaluate the effects — is able to target, delete, replace, or modify only single gene sequences with a single guide RNA and has limited ability to assess multiple genetic changes simultaneously.

Now, however, Yale scientists have developed a series of sophisticated mouse models using CRISPR (“clustered regularly interspaced short palindromic repeats”) technology that allows them to simultaneously assess genetic interactions on a host of immunological responses to multiple diseases, including cancer.

The findings were published March 20 in the journal Nature Biomedical Engineering.

Women with polycystic ovary syndrome (PCOS) find it harder to get pregnant, have more frequent miscarriages and have a higher risk of developing endometrial cancer. Now, in a new study published in Nature Medicine, Swedish researchers have shown that the uterine lining of these women differs in terms of both the composition of individual cells and gene expression. The results open the door to new drug treatments.

Researchers from the University of Bath have developed an irreversible inhibitor of the transcription factor cJun, which drives certain difficult-to-treat cancers.

The Harrington Discovery Institute at University Hospitals and the American Society for Clinical Investigation have awarded Dr. Owen Witte(Link is external) (Link opens in new window) with the twelfth annual Harrington Prize for Innovation in Medicine.